Tot Biopharm, a private equity-backed Chinese cancer drug developer, has filed for a Hong Kong IPO under rules that allow for listings by pre-revenue biotech companies.
Founded in 2009, Tot has seven biological and five chemical drugs in the pipeline, according to a prospectus. One is currently in phase-three clinical trials and three more are in phase one. The most...
Investors see opportunity in bringing a promising currency exchange-focused fintech model from Europe into Southeast Asia. Singapore-focused YouTrip is the region’s first mover in this niche
Traditionally the overlooked, underappreciated or misrepresented facet of ESG, governance is gaining prominence in emerging markets private equity as investors reassess risk exposure
Capital has poured into China’s online education sector in recent years, but with losses mounting and valuations called into question, investors are finding that not all business models are created equal
Endiya Partners, an early-stage VC investor based in India, has achieved a first close of $40 million for its second fund. The target is $70 million.